Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Sorlí, Luisa
- dc.contributor.author Luque Pardos, Sònia
- dc.contributor.author Li, Jian
- dc.contributor.author Benítez-Cano, Adela
- dc.contributor.author Fernández, Xenia
- dc.contributor.author Prim, Núria
- dc.contributor.author Vega, Victoria
- dc.contributor.author Gómez Junyent, Joan
- dc.contributor.author López Montesinos, Inmaculada
- dc.contributor.author Gómez-Zorrilla, Silvia
- dc.contributor.author Montero, Maria Milagro
- dc.contributor.author Grau Cerrato, Santiago
- dc.contributor.author Horcajada Gallego, Juan Pablo
- dc.date.accessioned 2024-10-29T07:27:44Z
- dc.date.available 2024-10-29T07:27:44Z
- dc.date.issued 2023
- dc.description.abstract In some cases, colistin is the only treatment option for infections caused by the very drug-resistant Pseudomonas aeruginosa. However, in the past decade, there have been questions concerning its pharmacokinetics and concentration at the site of infection. In this scenario, its use in a difficult-to-treat infection like pneumonia is currently debatable. This is a clinical pharmacokinetic study of colistin in patients with multidrug-resistant P. aeruginosa pneumonia. Our findings demonstrate that colistin exposure is associated with worse clinical outcomes rather than better clinical outcomes, implying that other therapeutic options should be explored in this clinical setting.
- dc.format.mimetype application/pdf
- dc.identifier.citation Sorlí L, Luque S, Li J, Benítez-Cano A, Fernández X, Prim N, et al. Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa. Microbiol Spectr. 2023 Dec 12;11(6):e0296723. DOI: 10.1128/spectrum.02967-23
- dc.identifier.doi http://dx.doi.org/10.1128/spectrum.02967-23
- dc.identifier.issn 2165-0497
- dc.identifier.uri http://hdl.handle.net/10230/68379
- dc.language.iso eng
- dc.publisher American Society for Microbiology
- dc.relation.ispartof Microbiol Spectr. 2023 Dec 12;11(6):e0296723
- dc.rights © 2023 Sorlí et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Pseudomonas aeruginosa
- dc.subject.keyword Colistin
- dc.subject.keyword Pharmacokinetics
- dc.subject.keyword Pneumonia
- dc.title Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion